Feature | March 13, 2013

First Implant Made in Pivotal Trial Evaluating Amplatzer LAA Occluder

Device designed to prevention stroke in patients with atrial fibrillation without the use of warfarin

March 13, 2013 — St. Jude Medical Inc. announced the first patient implant in a new pivotal trial evaluating the company’s Amplatzer cardiac plug (ACP) for the prevention of stroke. The Amplatzer cardiac plug clinical trial is designed to determine if the ACP device is safe and effective in preventing thrombus (blood clots) from migrating out of the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AF) who have a high risk for stroke.

The ACP trial is a prospective, randomized, multicenter clinical study with an adaptive trial design that will enroll no fewer than 400 and no more than 3,000 patients at up to 90 sites in the United States and Canada. The trial compares the safety and efficacy of the ACP device to traditional medical treatment using long-term, blood-thinning medication.

Study investigator Christian Machado, M.D., director of electrophysiology at the Providence Hospital Heart Institute, Southfield, Mich., performed the first Amplatzer cardiac plug implant in the pivotal phase of the trial. The procedure was assisted by co-investigator Thomas Forbes, M.D., a pediatric interventional cardiologist.

“Patients with untreated atrial fibrillation are four to five times more likely to have a stroke, which greatly increases their risk of disability or death. Dr. Forbes and I consider the ACP trial an important study as we look for ways to reduce this risk,” said Machado. “We are excited to contribute research that may help expand treatment options for patients.”

The Amplatzer device has been the market leader for LAA occlusion since its introduction in 2008. A self-expanding occlusion device constructed from nitinol mesh, and delivered via catheter, the ACP device is designed to completely seal the LAA at its opening, and minimize blood clots from forming in the LAA and migrating into the bloodstream.

According to the American Heart Association, an estimated 2.7 million Americans have AF and the likelihood of developing it increases with age. Defined as a quivering or irregular heartbeat (arrhythmia), AF can lead to blood clots, stroke, heart failure and other heart-related complications. AF is the most common heart rhythm abnormality in people over the age of 65. During episodes of AF, the heart contracts at rapid and irregular intervals, which can increase the likelihood of clot formation in the LAA. If a clot is released from the LAA, it can enter the blood stream and potentially travel to the brain, resulting in a stroke.

Each ACP trial study site will have specialists in electrophysiology and interventional cardiology, forming a collaboration between the two specialties. “The current standard of care for the prevention of stroke is warfarin or other oral blood-thinning medications that can be difficult for some people to tolerate, and may carry a risk of serious complications such as bleeding,” said trial investigator James Hermiller, M.D., an interventional cardiologist from St. Vincent Hospital in Indianapolis. “As physicians, we are always looking for new ways to best treat our patients. We hope the ACP trial will prove that we can reduce the risk of stroke in patients with atrial fibrillation through this minimally invasive procedure.”

“The Amplatzer cardiac plug has shown great promise in international markets, and we look forward to establishing the evidence required to make it available in the U.S.,” said Frank J. Callaghan, president of the St. Jude Medical cardiovascular and ablation technologies division. “The ACP trial is another example of significant investment by St. Jude Medical to develop landmark clinical evidence. This trial will help us understand the long-term benefits of LAA occlusion therapy for lowering the risk of stroke in atrial fibrillation patients and potentially improve their quality of life.”

The device is currently not approved for use in the United States. The ACP trial is conducted under an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA).

For more information: www.sjm.com

Related Content

Sponsored Content | Case Study | Cardiovascular Ultrasound| January 21, 2016
This case study is from the Cardiac Imaging Department, Hospital Clinic, Barcelona, Spain.
Csound, GE ultrasound

4D Clarity, HDlive and cSound acquisition provide excellent TTE and TEE images.

Sponsored Content | Case Study | January 21, 2016
GE Healthcare is taking the next leap in image quality performance, quantification and workflow with the introduction
Ernest Shackleton, hole in the heart, Endurance 100th anniversary, Ian Calder
News | Structural Heart| January 20, 2016
On the 100th anniversary of the Endurance expedition to Antarctica led by Sir Ernest Shackleton, doctors writing in the...
pulmonary artery to left atrial shunt, heart lung transplant, Oswaldo, Stanford Children's Health

2015 was a year of dramatic changes for Oswaldo and his family, seen here at his bedside, post-transplant surgery in July. Photo courtesy of Business Wire.

Feature | Cardiovascular Surgery| January 15, 2016
2016 is starting off a whole lot better than last year for 14-year-old Oswaldo Jimenez of Salem, Ore. Last year at this...
CardioKinetix, Parachute device, heart failure, PARACHUTE IV trial, half enrollment
News | Heart Failure| January 15, 2016
CardioKinetix Inc. announced that it has enrolled more than half of the subjects in its pivotal United States trial,...
Sapien III, Sapien 3, PARTNER III

The Edwards Sapien 3 valve uses a skirt at its base to prevent paravalvular leak. This is the newest version of the Sapien and will be used in the upcoming PARTNER III Trial.

Feature | Heart Valve Repair| January 15, 2016 | Dave Fornell
January 15, 2016 — The U.S.
Watchman, LAA closure device, cost effectiveness, VIvek Reddy, stroke reduction, study
News | Left Atrial Appendage (LAA) Occluders| January 06, 2016
A new study determined that the Watchman left atrial appendage closure device is more cost-effective than warfarin and...
BioVentrix, Revivent-TC Ventricular Enhancement System, interventional heart failure

BioVentrix closed-chest Revivent-TC Ventricular Enhancement System reduces the size of the ventricle for more efficient pumping in heart failure patients.

News | Heart Failure| December 29, 2015
December 29, 2015 — BioVentrix in mid-December announced the successful completion of the 30th clinical case using th
watchman LAA occluder, LAAO registry

Implantation of the Boston Scientific Watchman LAA occluder.

News | Left Atrial Appendage (LAA) Occluders| December 29, 2015
December 29, 2015 — The American College of Cardiology (ACC) launched the new Left Atrial Appendage Occlusion (LAAO)

Photo courtesy of Vital Images

News | ACC| December 22, 2015
December 22, 2015 — In 2015, results from the ITALIC and CvLPRIT trials, along with studies examining lifestyle facto
Overlay Init